文献速递泌尿男性生殖肿瘤

转移性去势抵抗性前列腺癌患者同源重组修复基因体系或胚系变异的治疗模式与结局

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
PubMed 文献 · Ann Oncol · 2024-02-27

本研究汇总4项多中心观察性研究中729例接受一线雄激素受体信号抑制剂或紫杉类治疗的转移性去势抵抗性前列腺癌患者,按体系/胚系同源重组修复基因变异分为BRCA1/2突变组、HRR非BRCA突变组和无HRR变异组。BRCA组所有结局均显著劣于非BRCA组,HRR非BRCA组结局也显著劣于无HRR变异组。

要点

  • 729例中BRCA组96例(13.2%)、HRR非BRCA组127例(17.4%)、无HRR变异组506例(69.4%)。
  • BRCA组影像学无进展生存、PFS2和总生存均显著劣于非HRR组或非BRCA组(P<0.05)。
  • HRR非BRCA组影像学无进展生存、PFS2和总生存也显著劣于无HRR变异组。

核心结论

  • BRCA亚组转移性去势抵抗性前列腺癌患者的结局劣于非BRCA亚组(HRR非BRCA组或无HRR变异组)。
  • 尽管存在异质性,HRR非BRCA亚组结局仍劣于无HRR变异组。
  • 早期筛查HRR突变尤其是BRCA1/2对改善转移性去势抵抗性前列腺癌患者预后至关重要。

研究设计与样本

  • CAPTURE研究汇总4项多中心观察性研究的729例转移性去势抵抗性前列腺癌患者数据。
  • 入组要求一线接受雄激素受体信号抑制剂或紫杉类治疗、有足够肿瘤样本及生物标志物 panel 结果。
  • 采用包含ATM、BRCA1、BRCA2、BRIP1、CDK12、CHEK2、FANCA、HDAC2、PALB2、RAD51B和RAD54L的定制基因 panel 对配对正常与肿瘤DNA行二代测序。
  • 按体系/胚系变异分为BRCA1/2突变组(BRCA)、除BRCA1/2外的HRR突变组(HRR非BRCA)和无HRR变异组(非HRR)。
  • 无BRCA1/2突变者归类为非BRCA。

主要发现

  • 729例中BRCA组96例(13.2%)、HRR非BRCA组127例(17.4%)、非HRR组506例(69.4%)。
  • BRCA组所有结局均显著劣于非HRR组或非BRCA组(P<0.05)。
  • BRCA组PFS2和总生存显著短于HRR非BRCA组(P<0.05)。
  • HRR非BRCA组影像学无进展生存、PFS2和总生存均显著劣于非HRR组。
  • 探索性分析提示BRCA组中一线治疗选择(ARSi或紫杉类)或变异体系/胚系来源与结局无显著差异。

关键数值与推荐

  • BRCA组96例(13.2%)、HRR非BRCA组127例(17.4%)、非HRR组506例(69.4%)。
  • BRCA组所有结局显著劣于非HRR组或非BRCA组(P<0.05)。
  • BRCA组PFS2和总生存显著短于HRR非BRCA组(P<0.05)。
  • HRR非BRCA组影像学无进展生存、PFS2和总生存显著劣于非HRR组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination repair (HRR) genes and treatment outcomes in metastatic castration-resistant PC (mCRPC) is limited. The aim of this study was to investigate the prevalence and outcomes associated with somatic/germline HRR alterations, particularly BRCA1/2, in patients initiating first-line (1L) mCRPC treatment with androgen receptor signalling inhibitors (ARSi) or taxanes. PATIENTS AND METHODS: Data from 729 mCRPC patients were pooled for CAPTURE from four multicentre observational studies. Eligibility required 1L treatment with ARSi or taxanes, adequate tumour samples and biomarker panel results. Patients underwent paired normal and tumour DNA analyses by next-generation sequencing using a custom gene panel including ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2, RAD51B and RAD54L. Patients were divided into subgroups based on somatic/germline alteration(s): with BRCA1/2 mutations (BRCA); with HRR mutations except BRCA1/2 (HRR non-BRCA); and without HRR alterations (non-HRR). Patients without BRCA1/2 mutations were classified as non-BRCA. Radiographic progression-free survival (rPFS), progression-free survival 2 (PFS2) and overall survival (OS) were assessed. RESULTS: Of 729 patients, 96 (13.2%), 127 (17.4%) and 506 (69.4%) were in the BRCA, HRR non-BRCA and non-HRR subgroups, respectively. BRCA patients performed significantly worse for all outcomes than non-HRR or non-BRCA patients (P < 0.05), while PFS2 and OS were significantly shorter for BRCA than HRR non-BRCA patients (P < 0.05). HRR non-BRCA patients also had significantly worse rPFS, PFS2 and OS than non-HRR patients. Exploratory analyses suggested that for BRCA patients, there were no significant differences in outcomes associated with 1L treatment choice (ARSi or taxanes) or with the somatic/germline origin of the alterations. CONCLUSIONS: Worse outcomes were observed for mCRPC patients in the BRCA subgroup compared with non-BRCA subgroups, either HRR non-BRCA or non-HRR. Despite its heterogeneity, the HRR non-BRCA subgroup presented worse outcomes than the non-HRR subgroup. Screening early for HRR mutations, especially BRCA1/2, is crucial in improving mCRPC patient prognosis.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Olmos D, Lorente D, Alameda D, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024. PMID: 38417742. doi:10.1016/j.annonc.2024.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。